Haloperidol Richter

Haloperidol Richter is an oral medication containing the active ingredient haloperidol, a typical antipsychotic of the butyrophenone class, marketed in the European Union. It is supplied as a prescription product and is used under medical supervision for the management of certain psychiatric conditions. It is formulated for systemic absorption and does not contain additional active compounds. The product is intended for adult patients and should be prescribed by a healthcare professional.

Haloperidol Richter is indicated for the treatment of several acute and chronic psychiatric disorders.

- Schizophrenia, including maintenance therapy for stable patients. - Acute psychotic episodes associated with schizophrenia or other mental health disorders. - Manic episodes in bipolar disorder when rapid control of agitation is required. - Severe agitation or aggression in patients with underlying psychotic conditions.

Side effects of haloperidol may vary in frequency and severity, ranging from mild to potentially serious.

Common: - Drowsiness or sedation, which may affect daily activities. - Extrapyramidal symptoms such as tremor, rigidity, or restlessness (akathisia). - Dry mouth, leading to discomfort or dental issues.

Serious: - Tardive dyskinesia, a potentially irreversible movement disorder that can persist after discontinuation. - Neuroleptic malignant syndrome, characterized by fever, severe muscle rigidity, autonomic instability, and altered mental status. - Cardiac arrhythmias, including QT interval prolongation that may increase the risk of ventricular tachycardia.

When prescribing Haloperidol Richter, clinicians should consider several precautionary measures to minimize risks.

- Review patient history for cardiovascular disease, seizure disorders, or hepatic impairment. - Monitor for early signs of extrapyramidal symptoms, especially after dose changes. - Use caution in elderly patients, who may be more susceptible to sedation, falls, and orthostatic hypotension. - Evaluate pregnancy and lactation status; haloperidol is generally avoided unless benefits outweigh potential risks. - Assess concomitant medications that may prolong the QT interval. - Adjust dosing in patients with renal or hepatic dysfunction as recommended by clinical guidelines.

Haloperidol can interact with other drugs, affecting its efficacy or safety profile.

Avoid: - Other dopamine antagonists or high‑potency antipsychotics, which may increase the risk of extrapyramidal side effects. - Medications that significantly prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics, fluoroquinolones). - Strong CYP3A4 inhibitors such as ketoconazole or itraconazole, which can raise haloperidol plasma concentrations.

Use with caution: - CYP3A4 inducers like carbamazepine or phenytoin, which may reduce haloperidol levels and effectiveness. - Central nervous system depressants (e.g., benzodiazepines, opioids) that can enhance sedation and respiratory depression. - Anticholinergic agents that may mask early extrapyramidal symptoms, delaying detection.